Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT)

Pain Med. 2006 Mar-Apr;7(2):164-5. doi: 10.1111/j.1526-4637.2006.00107.x.

Abstract

A 47-year-old woman who underwent allogenic peripheral blood stem cell transplant developed withdrawal symptoms soon after Fentanyl 25 mcg/h patch was stopped, which has not been reported at this dose. Possible causes, such as the inhibition of CYP3A4 induced by cyclosporine causing elevations of serum fentanyl, are discussed.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / adverse effects
  • Analgesics, Opioid / metabolism
  • Back Pain / complications
  • Back Pain / drug therapy
  • Cyclosporine / adverse effects
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System / metabolism
  • Drug Interactions / physiology
  • Female
  • Fentanyl / administration & dosage
  • Fentanyl / adverse effects*
  • Fentanyl / metabolism
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Intervertebral Disc Displacement / complications
  • Intervertebral Disc Displacement / drug therapy
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / therapy
  • Middle Aged
  • Opioid-Related Disorders / etiology*
  • Opioid-Related Disorders / physiopathology
  • Peripheral Blood Stem Cell Transplantation / adverse effects*
  • Substance Withdrawal Syndrome / etiology*
  • Substance Withdrawal Syndrome / physiopathology

Substances

  • Analgesics, Opioid
  • Cytochrome P-450 Enzyme Inhibitors
  • Immunosuppressive Agents
  • Cyclosporine
  • Cytochrome P-450 Enzyme System
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Fentanyl